Claims
- 1. A therapeutic composition for the treatment of Acquired Immuno Deficiency Syndrome (AIDS), said composition comprising as an active ingredient of a complex of Poly(A).Poly(U) and anti-AIDS coagent which acts on the HIV according to a different mechanism from that of the complex of Poly (A).Poly(U) and pharmaceutically acceptable diluents or carriers.
- 2. The composition of claim 1 wherein the complex of Poly(A).Poly(U) is present in the amount of from about 100 mg to about 4,000 mg per unitary dose.
- 3. The composition of claim 1 wherein the complex of Poly(A).Poly(U) is present in the amount of from about 150 mg to about 1,000 mg per unitary dose.
- 4. The composition of claim 1 wherein the weight ratio of Poly(A).Poly(U) to the anti-AIDS coagent is from about 1:10.sup.-1 to about 1:10.sup.-4.
- 5. The composition of claim 4 wherein the said ratio is from about 1:10.sup.-1 to about 1:10.sup.-2.
- 6. A therapeutic composition according to claim 5 wherein the anti-AIDS coagent acting on the HIV according to a mechanism different from that one of the Poly(A).Poly(U) complex is selected from the group consisting of AZT, DDI, DDC and combinations of the foregoing.
- 7. The composition of claim 6 wherein the complex of Poly(A).Poly(U) is present in the amount of from about 100 mg to about 4,000 mg per unitary dose.
- 8. The composition of claim 6 wherein the complex of Poly(A).Poly(U) is present in the amount of from about 150 mg to about 1,000 mg per unitary dose.
- 9. The composition of claim 1 wherein the anti-AIDS coagent is AZT and wherein the weight ratio of Poly(A).Poly(U) to AZT is from about 1:10.sup.-1 to about 1:10.sup.-4.
- 10. The composition of claim 9 wherein the said ratio is from about 1:10.sup.-1 to about 1:10.sup.-2.
- 11. The composition of claim 10 wherein the complex of Poly(A).Poly(U) is present in the amount of from about 100 mg to about 4,000 mg per unitary dose.
- 12. The composition of claim 10 wherein the complex of Poly(A).Poly(U) is present in the amount of from about 150 mg to about 1,000 mg per unitary dose.
- 13. The composition of claim 10 wherein an unitary dose contains 150 mg of the complex Poly(A).Poly(U) associated with 15 mg of AZT.
Priority Claims (1)
Number |
Date |
Country |
Kind |
91-08085 |
Apr 1991 |
GBX |
|
PRIOR APPLICATIONS
This application is a division of U.S. patent application Ser. No. 582,658 filed Jan. 4, 1996 which is a continuation of U.S. patent application Ser. No. 437,219 filed May 8, 1995, now abandoned, which is a continuation of U.S. patent application Ser. No. 218,850 filed Mar. 28, 1994, now abandoned, which is a continuation of U.S. patent application Ser. No. 099,048 filed Jul. 28, 1993, now abandoned, which is a continuation of U.S. patent application Ser. No. 866,435 filed Apr. 10, 1992, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5063209 |
Carter |
Nov 1991 |
|
Non-Patent Literature Citations (3)
Entry |
Cell Biology International Reports, Vo. 14, Dec. 1980, No. 12. |
Journal of Immunology, vol. 117, pp. 423-427 Aug. 1976. |
Clinical Aspects of Interferons, pp. 319-331 1988. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
582658 |
Jan 1996 |
|
Continuations (4)
|
Number |
Date |
Country |
Parent |
437219 |
May 1995 |
|
Parent |
218850 |
Mar 1994 |
|
Parent |
99048 |
Jul 1993 |
|
Parent |
866435 |
Apr 1992 |
|